LUYE PHARMA (02186) subsidiary completed the issuance of 1.5 million shares of convertible preferred stock.

LUYE PHARMA (02186) announces that on December 12, 2025, the issuance of convertible preference shares has been completed according to the terms of the subscription agreement. The issuer, Luye Geneora Holding Limited (a wholly-owned subsidiary of the Company), has issued and distributed 1.5 million convertible preference shares to the subscriber. These convertible preference shares can be exchanged for the existing shares of BOAN BIOTECH held by the Group, and do not involve the issuance of any new shares by BOAN BIOTECH. Calculated at the initial exchange price of HK$11.718, the maximum number of BOAN BIOTECH shares deliverable after exchanging all convertible preference shares is 100,486,431 shares, representing approximately 16.15% of the total issued shares of BOAN BIOTECH as of the date of this announcement.